Glaucoma Therapeutics Market, By Drug Class (Alpha adrenergic Agonist, Beta Blockers, Prostaglandin Analogs, Carbonic Anhydrase Inhibitor, Cholinergic, Combined Medication, and Fixed-dose Combinations), By Disease Type (Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2029

Glaucoma may be a disease that damages the optic nerve and its progression could end in vision loss and blindness. Treatment of glaucoma starts with topical eye drops belonging to the category of prostaglandins, beta-blockers, alpha agonist, combination medication, carbonic anhydrase inhibitor, and cholinergic. Administration of those eye drops reduces the assembly of the fluid inside eyes, thereby decreasing pressure. Topical eye drops is an alternate for surgery or to delay a surgery. According to BrightFocus Foundation, glaucoma is prevalent in 3 million individuals in the U.S. and out of those; 2.7 million are aged more than 40 years. This slow progressing disorder is caused due to structural changes in the optical nerve causing blindness or varying level of visual loss. The increasing population of geriatric and improving diagnostic tools to detect glaucoma is aiding the glaucoma therapeutics market growth.

The Glaucoma Therapeutics Market accounted for 7.0 billion in 2020 and is estimated to be US$ 12.0 billion by 2029 and is anticipated to register a CAGR of 6.2%.

Impact of Covid-19 pandemic on market

With the outbreak of the COVID-19, various businesses are at the forefront to combat this pandemic. The corona virus outbreak has also caused a shortage in the supply of glaucoma drugs worldwide. This is because of the disruption in the supply chain especially in the production and shipment of the drugs that are manufactured in China and India. China along with India is the main countries that produce most generic drugs, which accounts for the majority of prescriptions in the USA. Therefore, this pandemic interrupted the critical supply chain and will cause a significant shortage in the availability of eye medications over the next few months. According to the Food And Drug Administration (FDA), some ophthalmology drugs (used for glaucoma and other eye related conditions) that are in shortage due to COVID-19 are Atropine Sulfate Ophthalmic Ointment, Bacitracin Ophthalmic Ointment, Cospot drops, Phospholine Iodide Ophthalmic Solution, Latanoprost Ophthalmic Solution, and others. This report will quantify the impact of pandemic on glaucoma therapeutics market.

The increasing prevalence of glaucoma among the geriatric population is one of the major factors to drive the market growth. The increasing use of screen gadgets like laptops and smart phones are the main cause for rising incidence of glaucoma. According to the International Agency for the Prevention of Blindness: 2017, glaucoma is second leading cause of blindness and leading cause of irreversible blindness worldwide. The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG). Moreover, PACG is most common in South-East Asian population while POAG is most common in white Caucasians and individuals of African origin. PACG is associated with a high risk of blindness as compared to POAG.

Increasing number of diabetic patients and geriatric population

Glaucoma may occur among the people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is related to abnormal vessel growth, which may end in retinopathy and results in blockage of natural drainage of the attention. Rapidly increasing geriatric population is one among the important factors for the increasing prevalence of glaucoma, which successively is projected to drive the expansion of the glaucoma therapeutics market in near future. For instance, per the International Diabetes Foundation (IDF) 2017 statistics, the number of individuals with diabetes aged between 20 to 79 years is increasing worldwide. Among which, Africa (156%) is accounted to register the highest diabetic population, followed by Middle East (110%), South East Asia (84%), Latin and Central America(62%), North America (35%), Europe (16%), and Western Pacific (15%). However, drugs recalls by major players is projected to hinder demand for glaucoma therapeutics.

The global glaucoma therapeutics market is segmented based on drug class, disease type, distribution channel, and region.

On the basis of drug class, the glaucoma therapeutics market is segmented into alpha adrenergic agonist, beta blockers, prostaglandin analogs, carbonic anhydrase inhibitor, cholinergic, combined medication, and fixed-dose combinations. Based on disease type, the target market is segmented into primary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG). Based on distribution channel, the target market segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

On region the global glaucoma therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds dominant position in glaucoma therapeutics market, followed by Asia Pacific. Increasing prevalence of diabetes, increasing ocular disorders, and increasing number of blind and visually impaired people in turn opting for glaucoma treatment are expected to drive growth of the glaucoma therapeutic market in this region. For instance, According to National Federation of the Blind, 2014, an estimated 10 million people in the U.S. are blind or visually impaired. It is estimated that around 1.3 million people are legally blind in the U.S. and the number is projected to increase to 75,000 people annually in the U.S.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the glaucoma therapeutics market report based on drug class, disease type, distribution channel and region.

Global Glaucoma Therapeutics Market, By Drug Class:

• Alpha adrenergic Agonist
• Beta Blockers
• Prostaglandin Analogs
• Carbonic Anhydrase Inhibitor
• Cholinergic
• Combined Medication
• Fixed-dose Combinations

Global Glaucoma Therapeutics Market, By Disease Type:

• Primary Open Angle Glaucoma (POAG)
• Primary Angle Closure Glaucoma (PACG)

Global Glaucoma Therapeutics Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Glaucoma Therapeutics Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global glaucoma therapeutics market includes Valeant Pharmaceuticals International, Inc., Allergan Inc., Merck KGaA, Fera Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Aristo Pharmaceuticals Pvt. Ltd., Santen Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, and Novartis AG. The key players in the market are focusing on organic growth strategies in order to gain maximum market share and retain leading position in the market. For instance, in December 2017, Aerie Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for Rhopressa (netarsudil ophthalmic solution) 0.02%, indicated for lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

• Valeant Pharmaceuticals International, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Allergan Inc.
• Merck KGaA
• Fera Pharmaceuticals, LLC
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Aristo Pharmaceuticals Pvt. Ltd.
• Santen Pharmaceutical Co., Ltd.
• Aerie Pharmaceuticals
• Novartis AG